They're a group of over-the-counter meds that are arguably the most trusted to soothe aches and fever—and two major stores ...

Results from a new study of Pfizer and Lilly’s non-opioid pain drug tanezumab have shown ... relative to nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with moderate-to-severe ...

The pharmaceutical giant halted the creation of danuglipron, an oral GLP-1 drug that was hoped would work like Ozempic in pill-form. Dr Chris Boshoff, Pfizer's Chief Scientific Officer ...

After a long and troubled development the fate of Pfizer/Lilly’s tanezumab ... developed of the two remaining drugs in development in the NGF class, in pain caused by osteoarthritis.

Market OverviewThe Global Osteoarthritis Pain Drugs Market is valued at USD 10.32 Billion in 2023 and is projected to reach a value of USD 17.96 Billion by 2032 at a CAGR (Compound Annual Growth Rate) ...

The LATAM pain management drugs market was valued at $2,683.82 million in 2019, and is projected to reach $3,383.20 million by 2027, registering a CAGR of 3.5% from 2020 to 2027. The length of pain ...

It's not yet clear which drugs were impacted, which drugs may be in shortage or how long a shortage could last. Pfizer said they are still assessing the damage and how it will impact production.